Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.56 |
| ▸ | PDE4A | P27815 | 2/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4216140 | 1.00 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4DPIK3CD | |
| SCHEMBL15508864 | 1.00 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4DPIK3CD | |
| SCHEMBL4218331 | 0.94 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4DPIK3CD | |
| SCHEMBL4204576 | 0.94 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4DPIK3CD | |
| SCHEMBL2814379 | 0.94 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4DPIK3CD | |
| SCHEMBL2575871 | 0.92 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DPIK3CD | |
| SCHEMBL30962804 | 0.89 | ALDH1A1 (0.49) | PDE4BPDE4APDE4CPDE4DPIK3CD | |
| SCHEMBL30912375 | 0.89 | ALDH1A1 (0.49) | PDE4BPDE4APDE4CPDE4DPIK3CD | |
| SCHEMBL20694370 | 0.88 | ALDH1A1 (0.48) | PDE4BPDE4APDE4CPDE4DPIK3CD | |
| SCHEMBL30140271 | 0.88 | GPR119 (0.57) | PDE4BPDE4APDE4CPDE4DPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
| EP-2029609-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146758-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | PDE4B 1799/4885PDE4A 1644/4885PDE4C 2287/4885 |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | PDE4B 1851/4885PDE4A 1636/4885PDE4C 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.